胃癌靶向及免疫治疗进展  

Progress of Targeted Therapy and Immunotherapy for Gastric Cancer

作　　者：郑宇[1] 潘宏铭[1] ZHENG Yu;PAN Hongming(Department of Oncology,Sir Run Run Shaw Hospital College of Medicine,Zhejiang University,Hangzhou 310063,China)

机构地区：[1]浙江大学医学院附属邵逸夫医院肿瘤内科,杭州310063

出　　处：《肿瘤防治研究》2024年第4期234-239,共6页Cancer Research on Prevention and Treatment

摘　　要：胃癌是中国常见的消化道恶性肿瘤,具有发病率和死亡率高、进展期患者占比高的特点。既往胃癌的治疗以化疗为主,HER2阳性胃癌可应用曲妥珠单抗。由于胃癌的高度异质性,以致胃癌的药物研发及临床研究进展不尽人意。近几年,随着免疫治疗的进展及新靶点在胃癌中的探索,胃癌治疗取得了重大突破。本文就胃癌靶向和免疫治疗研究进展作简要综述。Gastric cancer(GC)is a common malignant tumor of the digestive tract in China.It is characterized by high morbidity,mortality,and proportion of patients in advanced stages.In the past years,chemotherapy was used as the main treatment for GC.Subsequently,targeted therapy with trastuzumab was approved to treat HER2-positive GC.However,the progress of drug development and clinical studies has been limited by the high heterogeneity of GC.In recent years,research on immunotherapy and new targets for therapeutic exploration in GC has made great strides.Herein,we provide a brief review of the progress of the research on targeted therapy and immunotherapy for GC.

关 键 词：胃癌 靶向治疗 免疫治疗 

分 类 号：R735.2[医药卫生—肿瘤]